Palonosétron Juta (Palonosetron)

Palonosetron, the active ingredient in Palonosétron Juta, is a selective 5‑HT₃ receptor antagonist presented as a sterile injectable solution for intravenous use. It is used to prevent chemotherapy‑induced nausea and vomiting in adult cancer patients. GNH USA supplies Palonosétron Juta as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

GNH USA supplies Palonosétron Juta as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Palonosetron is employed across several chemotherapy‑related pathways to control nausea and vomiting.

- Chemotherapy‑induced nausea and vomiting (CINV): Provides effective prophylaxis of acute and delayed CINV in adult patients. - Post‑operative nausea and vomiting (PONV): Reduces incidence of nausea and vomiting after surgery when used as part of a multimodal regimen. - Radiotherapy‑induced nausea and vomiting: Helps mitigate nausea associated with certain radiotherapy protocols. - Antiemetic prophylaxis in stem‑cell transplantation: Supports control of nausea and vomiting during high‑dose chemotherapy conditioning regimens.

Palonosetron is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache: mild to moderate intensity. - Constipation: occasional bowel movement changes. - Fatigue: transient tiredness. - Dizziness: brief episodes of light‑headedness. - Injection site erythema: mild redness at the infusion site.

Serious or Rare Side Effects: - Allergic reaction: rash, pruritus, or anaphylaxis. - QT prolongation: cardiac rhythm changes detectable on ECG. - Serotonin syndrome: rare when combined with other serotonergic agents. - Severe hypotension: notable drop in blood pressure. - Persistent vomiting despite therapy: may indicate inadequate response.

When using Palonosetron, consider the following safety measures:

- Cardiac monitoring: patients with known QT prolongation should be evaluated before administration. - Drug interactions: review concomitant serotonergic medications for additive effects. - Pregnancy: use only if the potential benefit outweighs the risk to the fetus. - Breastfeeding: assess risk versus benefit, as limited data are available. - Renal/hepatic impairment: dose adjustment may be required in severe dysfunction. - Store at below 25°C: keep in the original packaging, protect from moisture and light.

Palonosetron may interact with several drug classes; clinicians 

Major Interactions (Avoid): - Ondond ").

Moderate ").